Jonathan J. Hubbard

827 total citations · 1 hit paper
12 papers, 427 citations indexed

About

Jonathan J. Hubbard is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Jonathan J. Hubbard has authored 12 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Jonathan J. Hubbard's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Hepatitis C virus research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Jonathan J. Hubbard is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Hepatitis C virus research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Jonathan J. Hubbard collaborates with scholars based in United States, France and Norway. Jonathan J. Hubbard's co-authors include Richard S. Blumberg, Michał Pyzik, Inger Sandlie, Kine Marita Knudsen Sand, Jan Terje Andersen, Laura P. James, S. Michael Owens, Elizabeth M. Laurenzana, W. Brooks Gentry and Richard A. Lempicki and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and Blood.

In The Last Decade

Jonathan J. Hubbard

10 papers receiving 415 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Neonatal Fc Receptor (FcRn): A Misnomer?

2019 297 citations Michał Pyzik, Kine Marita Knudsen Sand et al. Frontiers in Immunology profile →

Peers

Countries citing papers authored by Jonathan J. Hubbard

Since Specialization

Citations

This map shows the geographic impact of Jonathan J. Hubbard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan J. Hubbard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan J. Hubbard more than expected).

Fields of papers citing papers by Jonathan J. Hubbard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan J. Hubbard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan J. Hubbard. The network helps show where Jonathan J. Hubbard may publish in the future.

Co-authorship network of co-authors of Jonathan J. Hubbard

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan J. Hubbard. A scholar is included among the top collaborators of Jonathan J. Hubbard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan J. Hubbard. Jonathan J. Hubbard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	A Model‐Based Meta‐Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials 2025 ·CPT Pharmacometrics & Systems Pharmacology ·Jean Carlos Serrano, John Maringwa, (unknown), Wouter Willems, (unknown), Jeroen Verhoeven, Jennifer Lynn Ford, Kuan‐Hsiang Gary Huang, Jonathan J. Hubbard, Jonathan French, Damayanthi Devineni, An Vermeulen, Chandni Valiathan	0
2	Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial 2025 ·The Lancet ·Ghaith Noaiseh, Kathy L. Sivils, Kim Campbell, (unknown), Kim Hung Lo, (unknown), Jocelyn H. Leu, (unknown), (unknown), Steven Leonardo, Li He, Jonathan J. Hubbard, Jacques-Éric Gottenberg	0
3	OA25 Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren’s disease: results from a Phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS) 2025 ·Lara D. Veeken ·Jacques-Éric Gottenberg, Kathy Moser Sivils, Kim Campbell, (unknown), Kim Hung Lo, (unknown), (unknown), Jonathan J. Hubbard, Ghaith Noaiseh	1
4	FcRn augments induction of tissue factor activity by IgG-containing immune complexes 2020 ·Blood ·Douglas B. Cines, С. В. Зайцев, Lubica Rauova, Ann H. Rux, Victoria Stepanova, Sriram Krishnaswamy, Amrita Sarkar, M. Anna Kowalska, Guohua Zhao, Alan E. Mast, (unknown), Keith R. McCrae, Mortimer Poncz, Jonathan J. Hubbard, Michał Pyzik, Richard S. Blumberg	25
5	FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity 2020 ·The Journal of Experimental Medicine ·Jonathan J. Hubbard, Michał Pyzik, Timo Räth, Lisa K. Kozicky, Kine Marita Knudsen Sand, Amit Gandhi, Algirdas Grevys, Stian Foss, (unknown), Jonathan N. Glickman, Edda Fiebiger, Derry C. Roopenian, Inger Sandlie, Jan Terje Andersen, Laura M. Sly, Kristi Baker, Richard S. Blumberg	34
6	The Neonatal Fc Receptor (FcRn): A Misnomer? breakdown → 2019 ·Frontiers in Immunology ·Michał Pyzik, Kine Marita Knudsen Sand, Jonathan J. Hubbard, Jan Terje Andersen, Inger Sandlie, Richard S. Blumberg	297
7	High interferon‐stimulated gene ISG‐15 expression affects HCV treatment outcome in patients co‐infected with HIV and HCV 2013 ·Journal of Medical Virology ·Antonios Katsounas, Jonathan J. Hubbard, (unknown), Xiaozhen Zhang, Diana R. Dou, Bhavana Shivakumar, Sophie L. Winter, JF Schlaak, Richard A. Lempicki, Henry Masur, Michael A. Polis, Shyam Kottilil, Anu Osinusi	12
8	Host Gene Expression Changes Correlating With Anti–HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a 2012 ·The Journal of Infectious Diseases ·Jonathan J. Hubbard, Teresa Greenwell‐Wild, (unknown), (unknown), Richard A. Lempicki, Sharon M. Wahl, David M. Asmuth, Robert L. Murphy, Richard B. Pollard, Shyam Kottilil	18
9	Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats 2011 ·International Immunopharmacology ·Jonathan J. Hubbard, Elizabeth M. Laurenzana, David Williams, W. Brooks Gentry, S. Michael Owens	5
10	Complications and Outcomes of Brown Recluse Spider Bites in Children 2011 ·Clinical Pediatrics ·Jonathan J. Hubbard, Laura P. James	23
11	Extra-Hepatic Replication of the Hepatitis C Virus: Current Issues and Future Directions 2011 ·Future Virology ·Jonathan J. Hubbard, Shyam Kottilil	1
12	The Fate and Function of Therapeutic Antiaddiction Monoclonal Antibodies across the Reproductive Cycle of Rats 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Jonathan J. Hubbard, Elizabeth M. Laurenzana, David Williams, W. Brooks Gentry, S. Michael Owens	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact